Lucid Diagnostics Inc. — Form 8-K
Filed October 22, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 18/100
What the filing says
Lucid Diagnostics filed a Certificate of Designation for Series C Convertible Preferred Stock (up to 15,000 shares at $1,000 stated value = $15M maximum) convertible into common stock at $0.3519/share. The stock carries a 20% quarterly dividend in common shares, 300% liquidation preference, and mandatory conversion if common stock trades above $5.00 for 20 days after 24 months or above conversion price after March 31, 2030. Registration rights require S-1 filing within 120 days of closing, effectiveness within 60 days thereafter.
Why this rating
Equity raise of $15M is ~18% of $82.7M market cap—material for funding but standard financing. High dilution and onerous terms (300% liquidation, dividend accrual) are concerning but typical for distressed biotech. No material operational impact disclosed.
See more from October 22, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.